Tinuo Meibo's Sci-Tech Innovation Board IPO has been "under inquiry". The core product Steduta monoclonal antibody injection was approved for listing in China in February this year.

On August 11, Zhuhai Tianomabo Pharmaceutical Co., Ltd. (referred to as Tianomabo) applied for a change in the status of the listing review on the Science and Technology Innovation Board of the Shanghai Stock Exchange to "inquiry". Huatai United Securities is the sponsor for the IPO, with plans to raise 1.5 billion yuan. The prospectus shows that Tianomabo is an innovative biopharmaceutical company dedicated to blood product replacement therapy for global markets. After years of accumulation, the company has built core technology platforms with independent intellectual property rights, including the "high-throughput fully human monoclonal antibody R&D comprehensive technology platform HitmAb, the "high-efficiency antibody expression CHO-GS cell platform", the "process development platform", and the "biological analysis platform", cultivating core innovative drug technology capabilities covering key drug R&D and industrialization processes. The company's core product, Staduta monoclonal antibody injection (TNM002), also known as "Recombinant Anti-Tetanus Toxin Fully Human Monoclonal Antibody TNM002" with the brand name of 'Xin Titu', was approved for market sales in China in February 2025, making it the first-in-class recombinant anti-tetanus toxin monoclonal antibody drug globally. It was classified by Chinese CDE as a breakthrough therapy and included in the priority review program, the first domestically developed innovative biopharmaceutical in the field of anti-infectives to be classified as a breakthrough therapy, and was given Fast Track status by the US FDA, with groundbreaking significance globally in the field of tetanus prevention. The company's other core product, Recombinant Anti-Respiratory Syncytial Virus Fully Human Monoclonal Antibody TNM001, is a potential global third and China's first long-acting anti-RSV monoclonal antibody drug for the prevention of healthy and high-risk infants and young children. As of the signing date of this prospectus, TNM001 is undergoing Phase III clinical trials. The actual raised funds from this new stock issuance will be used for the company's main business projects and operating capital for the development of the main business, with specific investment projects outlined as follows: Financially, in the fiscal years 2022, 2024, and January-March 2025, Tianomabo's operating income was approximately 4.3398 million yuan, 15.0559 million yuan, and 0.1693 million yuan respectively. In fiscal years 2022, 2023, 2024, and January-March 2025, the company achieved a net profit of approximately -0.429 billion yuan, -0.446 billion yuan, -0.515 billion yuan, and -0.177 billion yuan respectively.